Sclerosing Bone Disorders

Genetics of Bone Biology and Skeletal Disease

Volumn , Issue , 2013, Pages 361-374

  Perdu, Bram ^a   Van Hul, Wim ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883940059     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387829-8.00023-8     Document Type: Chapter

References (135)

1. Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A 2011, 155A:943-968.
2. Smahi A, Courtois G, Rabia SH, Doffinger R, Bodemer C, Munnich A, et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002, 11:2371-2375.
3. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007, 39:960-962.
4. Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008, 83:64-76.
5. Sly WS, Whyte MP, Sundaram V, Tashian RE, Hewett-Emmett D, Guibaud P, et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. New Engl J Med 1985, 313:139-145.
6. Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, et al. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet 2000, 9:2059-2063.
7. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001, 104:205-215.
8. Pangrazio A, Poliani PL, Megarbane A, Lefranc G, Lanino E, Di Rocco M, et al. Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner Res 2006, 21:1098-1105.
9. Chalhoub N, Benachenhou N, Rajapurohitam V, Pata M, Ferron M, Frattini A, et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med 2003, 9:399-406.
10. Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, Perdu B, et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest 2007, 117:919-930.
11. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 2001, 10:2861-2867.
12. Gelb BD, Shi GP, Chapman HA, Desnick RJ Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273:1236-1238.
13. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70:11-19.
14. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. New Engl J Med 2002, 346:1513-1521.
15. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39:91-97.
16. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
17. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
18. Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet 2009, 41:95-100.
19. Hellemans J, Preobrazhenska O, Willaert A, et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet 2004, 36:1213-1218.
20. Nurnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, Ritter H, et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001, 28:37-41.
21. Reichenberger E, Tiziani V, Watanabe S, Park L, Ueki Y, Santanna C, et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet 2001, 68:1321-1326.
22. Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet 2000, 26:273-275.
23. Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet 2000, 26:19-20.
24. Vanhoenacker FM, De Beuckeleer LH, Van Hul W, Balemans W, Tan GJ, Hill SC, et al. Sclerosing bone dysplasias: genetic and radioclinical features. Eur Radiol 2000, 10:1423-1433.
25. Roodman GD Cell biology of the osteoclast. Exp Hematol 1999, 27:1229-1241.
26. Bruzzaniti A, Baron R Molecular regulation of osteoclast activity. Rev Endocr Metab Disord 2006, 7:123-139.
27. Balemans W, Van Wesenbeeck L, Van Hul W A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int 2005, 77:263-274.
28. de Vernejoul MC Sclerosing bone disorders. Best Pract Res Clin Rheumatol 2008, 22:71-83.
29. Del Fattore A, Cappariello A, Teti A Genetics, pathogenesis and complications of osteopetrosis. Bone 2008, 42:19-29.
30. Marks SC Osteopetrosis-multiple pathways for the interception of osteoclast function. Appl Pathol 1987, 5:172-183.
31. Villa A, Guerrini MM, Cassani B, Pangrazio A, Sobacchi C Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif Tissue Int 2009, 84:1-12.
32. Roth P, Stanley ER The biology of CSF-1 and its receptor. Curr Top Microbiol Immunol 1992, 181:141-167.
33. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444.
34. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW, Ahmed-Ansari A, Sell KW, Pollard JW, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A 1990, 87:4828-4832.
35. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
36. Kim N, Odgren PR, Kim DK, Marks SC, Choi Y Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A 2000, 97:10905-10910.
37. Takayanagi H Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
38. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
39. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem 1998, 273:28355-28359.
40. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
41. Blair HC, Robinson LJ, Zaidi M Osteoclast signalling pathways. Biochem Biophys Res Commun 2005, 328:728-738.
42. Boyle WJ, Simonet WS, Lacey DL Osteoclast differentiation and activation. Nature 2003, 423:337-342.
43. Lee ZH, Kim HH Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 2003, 305:211-214.
44. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004, 279:45969-45979.
45. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, et al. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 2007, 176:877-888.
46. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428:758-763.
47. Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A 2004, 101:6158-6163.
48. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
49. Whyte MP Carbonic anhydrase II deficiency. Clin Orthop Relat Res 1993, 52-63.
50. Fasth A, Porras O Human malignant osteopetrosis: pathophysiology, management and the role of bone marrow transplantation. Pediatr Transplant 1999, 3(Suppl. 1):102-107.
51. Wilson CJ, Vellodi A Autosomal recessive osteopetrosis: diagnosis, management, and outcome. Arch Dis Child 2000, 83:449-452.
52. Andren L, Dymling JF, Hogeman KE, Wendeberg B Osteopetrosis acro-osteolytica. A syndrome of osteopetrosis, acro-osteolysis and open sutures of the skull. Acta Chir Scand 1962, 124:496-507.
53. Tolar J, Teitelbaum SL, Orchard PJ Osteopetrosis. New Engl J Med 2004, 351:2839-2849.
54. Bastani B, Ross FP, Kopito RR, Gluck SL Immunocytochemical localization of vacuolar H+-ATPase and Cl--HCO3- anion exchanger (erythrocyte band-3 protein) in avian osteoclasts: effect of calcium-deficient diet on polar expression of the H+-ATPase pump. Calcif Tissue Int 1996, 58:332-336.
55. Ramirez A, Faupel J, Goebel I, Stiller A, Beyer S, Stockle C, et al. Identification of a novel mutation in the coding region of the grey-lethal gene OSTM1 in human malignant infantile osteopetrosis. Hum Mutat 2004, 23:471-476.
56. Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 2006, 440:220-223.
57. Bollerslev J, Grodum E, Grontved A Autosomal dominant osteopetrosis (a family study). J Laryngol Otol 1987, 101:1088-1091.
58. Bollerslev J Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. Endocr Rev 1989, 10:45-67.
59. Van Hul E, Gram J, Bollerslev J, Van Wesenbeeck L, Mathysen D, Andersen PE, et al. Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. J Bone Miner Res 2002, 17:1111-1117.
60. Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M, Abinun M, et al. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res 2003, 18:1740-1747.
61. Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, et al. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 2003, 18:1513-1518.
62. Nakamura I, Duong le T, Rodan SB, Rodan GA Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 2007, 25:337-344.
63. Coxon FP, Taylor A Vesicular trafficking in osteoclasts. Semin Cell Dev Biol 2008, 19:424-433.
64. Van Wesenbeeck L, Van Hul W Lessons from osteopetrotic mutations in animals: impact on our current understanding of osteoclast biology. Crit Rev Eukaryot Gene Express 2005, 15:133-162.
65. Sugiura Y, Yamada Y, Ko J Pycnodysostosis in Japan: report of six cases and a review of Japaneses literature. Birth Defects Orig Artic Ser 1974, 10:78-98.
66. Maroteaux P, Lamy M [Pyknodysostosis.]. Presse Med 1962, 70:999-1002.
67. Donnarumma M, Regis S, Tappino B, Rosano C, Assereto S, Corsolini F, et al. Molecular analysis and characterization of nine novel CTSK mutations in twelve patients affected by pycnodysostosis. Mutation in brief #961. Online. Hum Mutat 2007, 28:524.
68. Bromme D, Okamoto K, Wang BB, Biroc S Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996, 271:2126-2132.
69. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochemical Biophys Res Commun 1995, 206:89-96.
70. Shi GP, Chapman HA, Bhairi SM, DeLeeuw C, Reddy VY, Weiss SJ Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett 1995, 357:129-134.
71. Li YP, Alexander M, Wucherpfennig AL, Yelick P, Chen W, Stashenko P Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas. J Bone Miner Res 1995, 10:1197-1202.
72. Everts V, Aronson DC, Beertsen W Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif Tissue Int 1985, 37:25-31.
73. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
74. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
75. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
76. Canalis E, Pash J, Varghese S Skeletal growth factors. Crit Rev Eukaryot Gene Expr 1993, 3:155-166.
77. Perdu B, Van Hul W Sclerosing bone disorders: too much of a good thing. Crit Rev Eukaryot Gene Expr 2010, 20:195-212.
78. Piters E, Boudin E, Van Hul W Wnt signaling: a win for bone. Arch Biochem Biophys 2008, 473:112-116.
79. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
80. Balemans W, Devogelaer JP, Cleiren E, Piters E, Caussin E, Van Hul W Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res 2007, 22:708-716.
81. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72:763-771.
82. Katoh M WNT and FGF gene clusters (review). Int J Oncol 2002, 21:1269-1273.
83. Tanaka K, Kitagawa Y, Kadowaki T Drosophila segment polarity gene product porcupine stimulates the posttranslational N-glycosylation of wingless in the endoplasmic reticulum. J Biol Chem 2002, 277:12816-12823.
84. Zhai L, Chaturvedi D, Cumberledge S Drosophila Wnt-1 undergoes a hydrophobic modification and is targeted to lipid rafts, a process that requires porcupine. J Biol Chem 2004, 279:33220-33227.
85. Glass DA, Karsenty G Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. Ann N Y Acad Sci 2006, 1068:117-130.
86. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382:638-642.
87. Westendorf JJ, Kahler RA, Schroeder TM Wnt signaling in osteoblasts and bone diseases. Gene 2004, 341:19-39.
88. Günther T, Schüle R Fat or bone? A non-canonical decision. Nat Cell Biol 2007, 9:1229-1231.
89. Kubota T, Michigami T, Ozono K Wnt signaling in bone metabolism. J Bone Miner Metab 2009, 27:265-271.
90. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006, 119:1283-1296.
91. Kubota T, Michigami T, Sakaguchi N, Kokubu C, Suzuki A, Namba N, et al. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd. J Bone Miner Res 2008, 23:1661-1671.
92. Beighton P, Davidson J, Durr L, Hamersma H Sclerosteosis-an autosomal recessive disorder. Clin Genet 1977, 11:1-7.
93. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005, 16:319-327.
94. Van Buchem FS, Hadders HN, Ubbens R An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol 1955, 44:109-120.
95. Van Hul W, Balemans W, Van Hul E, Dikkers FG, Obee H, Stokroos RJ, et al. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. Am J Hum Genet 1998, 62:391-399.
96. Balemans W, Van Den Ende J, Freire Paes-Alves A, Dikkers FG, Willems PJ, Vanhoenacker F, et al. Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. Am J Hum Genet 1999, 64:1661-1669.
97. Piters E, Culha C, Moester M, Van Bezooijen RL, Adriaensen D, Mueller T, et al. First Missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum Mutat 2010, 31:E1526-E1543.
98. Semenov MV, He X Lrp5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 2006, 281:38276-38284.
99. Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 2005, 25:4946-4955.
100. Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int 2008, 82:445-453.
101. Leupin O, Piters E, Boudin E, De Freitas F, Bueno M, Ramos F, et al. Bone overgrowth-associated mutations in LRP4 impair sclerostin-facilitator function. J Biol Chem 2011, 286:19489-19500.
102. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001, 3:683-686.
103. Wang K, Zhang Y, Li X, Chen L, Wang H, Wu J, et al. Characterization of the Kremen-binding site on Dkk1 and elucidation of the role of Kremen in Dkk-mediated Wnt antagonism. J Biol Chem 2008, 283:23371-23375.
104. Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP, et al. Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J Biol Chem 2000, 275:4374-4382.
105. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999, 398:431-436.
106. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
107. Heath MJ, Hen R Serotonin receptors. Genetic insights into serotonin function. Curr Biol 1995, 5:997-999.
108. Yadav VK, Karsenty G Leptin-dependent co-regulation of bone and energy metabolism. Aging 2009, 1:954-956.
109. Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, Robinson DR, et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011, 17:684-691.
110. Voorhoeve N L'image radiologique non encore décrite d'une anomalie du squelette. Acta Radiol 1924, 3.
111. Hurt RL Osteopathia striata-Voorhoeve's disease; report of a case presenting the features of osteopathia striata and osteopetrosis. J Bone Joint Surg Br 1953, 35-B:89-96.
112. Perdu B, de Freitas F, Frints SG, Schouten M, Schrander-Stumpel C, Barbosa M, et al. Osteopathia striata with cranial sclerosis due to WTX gene defect. J Bone Miner Res 2009, 25:82-90.
113. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007, 315:642-645.
114. Rivera MN, Kim WJ, Wells J, Stone A, Burger A, Coffman EJ, et al. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci U S A 2009, 106:8338-8343.
115. Joseph, D.J., Ichikawa, S. and Econs, M.J. Mosaicism in osteopathia striata with cranial sclerosis. J Clin Endocrinol Metab, 95, 1506-7.
116. Happle R, Lenz W Striation of bones in focal dermal hypoplasia: manifestation of functional mosaicism?. Br J Dermatol 1977, 96:133-135.
117. Wang X, Reid Sutton V, Omar Peraza-Llanes J, Yu Z, Rosetta R, Kou YC, et al. Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. Nat Genet 2007, 39:836-838.
118. Berlin R, Hedensiö B, Lilja B, Linder L Osteopoikilosis-a clinical and genetic study. Acta Med Scand 1967, 181:305-314.
119. Lagier R, Mbakop A, Bigler Osteopoikilosis: a radiological and pathological study. Skeletal Radiol 1984, 11:161-168.
120. Giro MG, Duvic M, Smith LT, et al. Buschke-Ollendorff syndrome associated with elevated elastin production by affected skin fibroblasts in culture. J Invest Dermatol 1992, 99:129-137.
121. Debeer P, Pykels E, Lammens J, Devriendt K, Fryns JP Melorheostosis in a family with autosomal dominant osteopoikilosis: report of a third family. Am J Med Genet A 2003, 119A:188-193.
122. Zhang Y, Castori M, Ferranti G, Paradisi M, Wordsworth BP Novel and recurrent germline LEMD3 mutations causing Buschke-Ollendorff syndrome and osteopoikilosis but not isolated melorheostosis. Clin Genet 2009, 75:556-561.
123. Brons R, Koudstaal J Craniometaphyseal dysplasia. Oral Surg Oral Med Oral Pathol 1969, 28:202-215.
124. Penchaszadeh VB, Gutierrez ER, Figueroa E Autosomal recessive craniometaphyseal dysplasia. Am J Med Genet 1980, 5:43-55.
125. Taylor DB, Sprague P Dominant craniometaphyseal dysplasia-a family study over five generations. Australas Radiol 1989, 33:84-89.
126. Kirsch T, Kim HJ, Winkles JA Progressive ankylosis gene (ank) regulates osteoblast differentiation. Cells Tissues Organs 2009, 189:158-162.
127. Baynam G, Goldblatt J, Schofield L Craniometaphyseal dysplasia and chondrocalcinosis cosegregating in a family with an ANKH mutation. Am J Med Genet A 2009, 149A:1331-1333.
128. Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, et al. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet 2006, 43:1-11.
129. Saito T, Kinoshita A, Yoshiura K, Makita Y, Wakui K, Honke K, et al. Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1. J Biol Chem 2001, 276:11469-11472.
130. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009, 15:757-765.
131. Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 2008, 366:483-488.
132. Naveh Y, Alon U, Kaftori JK, Berant M Progressive diaphyseal dysplasia: evaluation of corticosteroid therapy. Pediatrics 1985, 75:321-323.
133. Chen JS, Sambrook PN Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol 2011, 2011(Sep):6.
134. Marie PJ, Kassem M Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol 2011, 165:1-10.
135. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011, 26:1012-1021.